News
Scotland appoints women’s health champion to tackle gender inequalities
Professor Anna Glasier OBE becomes Scotland’s first women’s health champion
The Scottish Government has appointed the country’s first women’s health champion to improve access to care and reduce inequalities.
Professor Anna Glasier will work with partners in the NHS and across the public and third sectors to drive forward actions in the Women’s Health Plan.
In 2021, Scotland became the first country in the UK to have a Women’s Health Plan, outlining ambitious improvement and change.
The initiative set out 66 actions to develop better treatment options for women and ensure they enjoy the best possible care throughout their lives.
Prof Glasier’s appointment coincides with the publication of the first Women’s Health Plan report which details the progress made so far on raising awareness around women’s health, improving access to and reducing inequalities.
Her priorities will include specialist menopause services, menstrual health with a focus on endometriosis and polycystic ovarian syndrome and heart health.
Minister for Public Health, Maree Todd said: “I am very pleased to welcome Prof Glasier to the role of women’s health champion.
“Her appointment is an important step forward in our work to reduce the unacceptable health inequalities that women continue to face.
“She has a wealth of knowledge and a passion for women’s health and will bring huge value to the role.”
Prof Glasier said: “I am honoured to have been invited to champion women’s health in Scotland.
“Scotland has a long tradition of being courageous in its approach to women’s health and the ambitious Women’s Health Plan is no exception, recognising as it does the inequalities which affect women in many areas of health.”
She added: “I am eagerly looking forward to starting in the role and supporting progress with the medium and longer term actions set out in the plan.”
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Fertility4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur5 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
News4 weeks agoVerdane invest in Clue to accelerate the future of women’s health






